Stockscreener 앱 받기
4.71
5.61%
-0.28
시간 외 거래:
4.79
0.08
+1.70%
전일 마감가:
$4.99
열려 있는:
$4.82
하루 거래량:
45,288
Relative Volume:
0.14
시가총액:
$88.09M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.80%
1개월 성능:
-29.07%
6개월 성능:
-19.21%
1년 성능:
+0.00%
1일 변동 폭
$4.67
$4.99
1주일 범위
$4.67
$5.45
52주 변동 폭
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
명칭
Kalaris Therapeutics Inc
전화
650-249-2727
주소
628 MIDDLEFIELD ROAD, PALO ALTO
KLRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.71 | 93.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-07-23 | 재개 | Piper Sandler | Neutral |
| 2025-05-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-08 | 개시 | William Blair | Outperform |
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Citizens Jmp Begins Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - MarketBeat
What to expect from Kalaris Therapeutics Inc. in the next 30 daysLong Setup & Consistent Growth Stock Picks - newser.com
How resilient is Kalaris Therapeutics Inc. stock in market downturnsGap Up & High Accuracy Investment Entry Signals - newser.com
Does Kalaris Therapeutics Inc. qualify in momentum factor screeningWeekly Investment Report & Verified Stock Trade Ideas - newser.com
What MACD and RSI say about Kalaris Therapeutics Inc.Weekly Trend Recap & Daily Profit Maximizing Trade Tips - newser.com
Analyzing Kalaris Therapeutics Inc. with risk reward ratio chartsMarket Trend Report & Weekly Stock Breakout Alerts - newser.com
Kalaris Therapeutics Appoints Matthew Gall as Chief Financial Officer - VisionMonday.com
Tools to assess Kalaris Therapeutics Inc.’s risk profile2025 EndofYear Setup & Weekly Market Pulse Alerts - newser.com
Identifying reversal signals in Kalaris Therapeutics Inc.Bull Run & Growth-Oriented Investment Plans - newser.com
Citizens Initiates Coverage of Kalaris Therapeutics (KLRS) with Market Outperform Recommendation - Nasdaq
Kalaris Therapeutics appoints Matthew Gall as chief financial officer By Investing.com - Investing.com Nigeria
KLRS Sees New Analyst Rating: Citizens Initiates with Market Out - GuruFocus
Can trapped investors hope for a rebound in Kalaris Therapeutics Inc.Bull Run & Real-Time Chart Breakout Alerts - newser.com
Will Kalaris Therapeutics Inc. outperform the marketMarket Trend Summary & Risk Managed Investment Signals - newser.com
How Kalaris Therapeutics Inc. stock performs in rate cut cycles2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
Kalaris Therapeutics Appoints New CFO Matthew Gall - TipRanks
Kalaris Therapeutics appoints Matthew Gall as chief financial officer - Investing.com
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer - The Manila Times
Kalaris (KLRS) names Matthew Gall CFO amid Phase 1b/2 nAMD study enrollment - Stock Titan
What’s next for Kalaris Therapeutics Inc. stock price2025 Short Interest & Target Return Focused Stock Picks - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - newser.com
Is Kalaris Therapeutics Inc. stock positioned for digital transformationQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
Citizens initiates Kalaris stock with Market Outperform rating, $20 price target By Investing.com - Investing.com South Africa
Citizens initiates Kalaris stock with Market Outperform rating, $20 price target - Investing.com
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Declines By 40.5% - MarketBeat
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsJuly 2025 WrapUp & Weekly Watchlist of Top Performers - newser.com
Kalaris Therapeutics Inc. stock outlook for YEAR2025 Performance Recap & Community Verified Watchlist Alerts - newser.com
Kalaris Therapeutics Inc (KLRS) 재무 분석
Kalaris Therapeutics Inc (KLRS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):